NVO vs SEPN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. NVO and SEPN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined NVO and SEPN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. Its franchise centers on GLP-1 receptor agonists, most notably semaglutide, sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. Novo Nordisk also holds a long-standing leadership position in insulin and broader diabetes therapies, and maintains smaller franchises in rare blood and endocrine disorders. The company is headquartered in Bagsvaerd, Denmark, and is controlled by the Novo Nordisk Foundation through a dual-share structure. US investors typically access it through the NVO American Depositary Receipt listed on the New York Stock Exchange, which represents the Danish B shares. The explosive demand for GLP-1 drugs for both diabetes and weight loss has made Novo Nordisk one of Europe's most valuable companies, while also straining its manufacturing capacity for injectable medicines.

Full NVO guide

Septerna, Inc. designs oral small molecule drugs against G protein-coupled receptors, the receptor family that sits behind roughly a third of approved medicines but which has historically been drugged with injectables or with molecules found by luck rather than by design. Its Native Complex Platform reconstitutes GPCRs outside the cell in a form stable enough to screen and to solve structurally, which is what lets the company go after targets that are usually reached with peptides or antibodies. Three efforts define the pipeline in 2026: SEP-631, an oral MRGPRX2 antagonist aimed at chronic spontaneous urticaria; SEP-479, a next-generation oral PTH1R agonist for hypoparathyroidism; and a global collaboration with Novo Nordisk on oral GPCR programs in obesity, type 2 diabetes and other cardiometabolic disease. The company listed on the Nasdaq in October 2024 with an upsized IPO that raised about $288 million.

Full SEPN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• NVO drivers: GLP-1 obesity and diabetes demand; Pipeline and next-generation candidates.
• SEPN drivers: The Novo Nordisk collaboration; SEP-631 into Phase 2b.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Novo Nordisk is heavily concentrated in a single drug class, so any clinical setback, safety signal, or faster-than-expected competition from Eli Lilly's tirzepatide (Mounjaro, Zepbound) and newer entrants directly threatens the core franchise. For SEPN, every clinical-stage biotech carries binary risk, and here it has already been demonstrated: SEP-786 was discontinued in February 2025 after two severe cases of elevated unconjugated bilirubin, and the stock fell 47% that day.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick NVO if you believe its drivers more; SEPN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the NVO and SEPN guides.

NVO. Novo Nordisk has historically commanded a premium pharma multiple on the strength of GLP-1 growth and very high margins. The multiple is sensitive to GLP-1 market-share dynamics versus Eli Lilly, supply progress, and US pricing news; disappointing trial data or share loss can compress it quickly. All figures are approximate, are reported in Danish kroner and translated to dollars, and should be verified against the latest filings.

SEPN. Price to sales of roughly 22 times shows up on screeners, but the denominator is partnership revenue on a recognition schedule, so the ratio does not describe a commercial business and comparing it to a specialty pharma multiple is not meaningful. The more useful framing is enterprise value: about $2.2 billion of market cap against roughly $516 million of cash leaves close to $1.7 billion attributed to a pipeline whose most advanced asset is entering Phase 2b. Analysts covering the stock are clustered around $49 to $51 after the August 2026 target raises, which is close to where the shares already trade.

Headline figures (approximate, early 2026): NVO shows revenue (ttm) ~$40 billion (approximate, verify; reported in Danish kroner), operating margin ~45% (approximate, verify), net margin ~35% (approximate, verify), glp-1 share of revenue Majority of sales from semaglutide products (approximate); SEPN shows revenue (ttm) ~$99 million, essentially all collaboration revenue from Novo Nordisk rather than product sales, revenue (q2 2026) ~$26.8 million versus consensus near $19.2 million, net loss (ttm) ~$24 million, or about $0.54 per share, cash ~$516.5 million at June 30, 2026, guided to fund operations at least into 2029.

NVO and SEPN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined NVO and SEPN exposure against your real portfolio. It is not an investment adviser.